Skip to main content
. 2015 Mar 12;7(3):605–619. doi: 10.1080/19420862.2015.1026501

Figure 5.

Figure 5.

(A) Mean (±SD) serum concentrations of ABT-981 following a 5 mg/kg intravenous () or subcutaneous () dose in male BALB/c mice. (B) Mean (±SD) serum concentrations of ABT-981 following a 4 mg/kg intravenous (Inline graphic) or subcutaneous (Inline graphic) dose in male Sprague‑Dawley rats. (C) ABT-981 serum concentrations following a single 5 mg/kg intravenous (Monkey 1: Inline graphic and Monkey 2 Inline graphic) or subcutaneous (Monkey 3: Inline graphic and Monkey 4:Inline graphic) dose in female Cynomolgus monkeys (C).